Senseonics Holdings, Inc. (AMEX:SENS) is set to announce second quarter earning results on Monday 10th August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, SENS to report 2Q20 loss of $ 0.09 per share from revenue of $ 1.43 million.
For the full year, analysts anticipate top line of $ 8.12 million, while looking forward to loss of $ 0.42 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 15.00 million ~ $ 20.00 million
Click Here For More Historical Outlooks Of Senseonics Holdings, Inc.
Previous Quarter Performance
Senseonics Holdings, Inc. disclosed loss for the first quarter of $ 0.19 per share, from the revenue of $ 0.04 million. The quarterly revenues decreased 99.02 percent compared with the same quarter last year. Wall street analysts are predicting, SENS to report 1Q20 loss of $ 0.13 per share from revenue of $ 0.88 million. The bottom line results missed street analysts by $ 0.06 or 46.15 percent, at the same time, top line results fell short of analysts by $ 0.84 million or 95.45 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Senseonics Holdings, Inc.
Stock Performance
According to the previous trading day, closing price of SENS was $ 0.48, representing a 33.33 % increase from the 52 week low of $ 0.36 and a 73.03 % decrease over the 52 week high of $ 1.78.
The company has a market capital of $ 108.36 million and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”SENS” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Senseonics Holdings, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.senseonics.com
Senseonics Holdings, Inc., a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days. The company has a collaboration agreement Roche Diabetes Care, Inc.
